Table 2 Adverse events during the extension study (safety analysis set)
|  | Maintenance group (n = 70) | Switch group (n = 78) | ||
|---|---|---|---|---|
Number | % | Number | % | |
All AEs | 49 | 70.0 | 55 | 70.5 |
All ADRs | 20 | 28.6 | 26 | 33.3 |
Serious AEs | 6 | 8.6 | 8 | 10.3 |
Serious ADRs | 3 | 4.3 | 4 | 5.1 |
Any AEs leading to discontinuation | 1 | 1.4 | 3 | 3.8 |
Any AEs leading to temporary drug interruption | 13 | 18.6 | 8 | 10.3 |
AEs experienced by ≥ 5% of patients in either group (by preferred term) | ||||
 Upper respiratory tract infection | 4 | 5.7 | 9 | 11.5 |
 Nasopharyngitis | 7 | 10.0 | 4 | 5.1 |
 Arthralgia | 3 | 4.3 | 8 | 10.3 |
 Cough | 3 | 4.3 | 4 | 5.1 |
Active tuberculosis | 0 | 0 | 0 | 0 |
Injection site reaction | 1 | 1.4 | 5 | 6.4 |